Cost-effectiveness Analysis of Two Regimens in the Treatment of Chronic Hepatitis B Fibrosis
10.6039/j.issn.1001-0408.2015.35.02
- VernacularTitle:两种方案治疗慢性乙型肝炎肝纤维化的成本-效果分析
- Author:
Peiling WANG
;
Jingying LI
;
Na FU
;
Xiaowan DUAN
- Publication Type:Journal Article
- Keywords:
Compound biejia ruangan tablet;
Anluo huaxian pill;
Chronic hepatitis B fibrosis;
Cost-effectiveness analysis
- From:
China Pharmacy
2015;26(35):4899-4901
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the cost-effectiveness of two regimens in the treatment of chronic hepatitis B fibrosis. METHODS:112 cases of chronic hepatitis B fibrosis were divided into Compound biejia ruangan tablet group (group A,n=56) and Anluo huaxian pill group(group B,n=56). Both groups received Entecavir dispersible tablets combined with relevant Chinese patent medicine. The liver fibrosis index and transient elastography of 2 group were detected before and after treatment,TCM symp-tom score and effective rate calculation were conducted to compare the cost-effectiveness of 2 groups. RESULTS:The cost,effec-tive rate and cost-effectiveness ratio of group A were 9 227.10 yuan,74.11% and 12 451;those of group B were 8 202.90 yuan, 69.28%and 11 840;incremental cost-effectiveness ratio was 21 205. Group B showed a better cost-effectiveness. Result of sensitiv-ity test was same to that of cost-effectiveness analysis. CONCLUSIONS:The cost-effectiveness of Anluo huaxian pill combined with Entecavir dispersible tables is better than Compound biejia ruangan tablet combined with Entecavir dispersible tables in the treatment of chronic hepatitis B fibrosis.
